Lundbeck

Lundbeck is an ethical research-based pharmaceutical company dedicated to becoming a world leader in the development of medicines for psychiatric and neurological diseases. We currently market medicines in the UK for depression and anxiety, schizophrenia, bipolar I disorder, Alzheimer’s and Parkinson’s disease and alcohol dependence, and have drugs in development for other central nervous system disorders.

Updated:
10 February 2016
Location:
National
Sectors:
Pharmaceutical, Clinical Commissioning Group, Local Authorities

1. Action Plan

1. The National Dementia Declaration lists seven outcomes that the DAA are seeking to achieve for people with dementia and their carers. How would you describe your organisation’s role in delivering better outcomes for people with dementia and their carers?

Lundbeck is dedicated to becoming a world leader in the development of medicines for psychiatric and neurological diseases such as depression and anxiety, schizophrenia, Alzheimer’s and Parkinson’s disease and alcohol dependence. 

Lundbeck are the marketing authorisation holders for one of the 4 licensed treatments recommended by NICE.  Clinicians now have pharmacological options, available on the NHS, for treating patients with mild, moderate and severe Alzheimer’s disease. Up until 2011 pharmacological options were limited to the moderate stage of the disease and this is the first time ever that clinicians have a pharmacological treatment recommended for severe AD.  These treatments are also endorsed for the behavioural and psychological symptoms of dementia (BPSD) in the new DH guidelines.  

Lundbeck through its promotional work and partnership activities with the NHS and care homes has focused on supporting clinicians and commissioners to ensure that funding for the new NICE recommendations was made available, so that all eligible patients have access to these treatments.  In addition we provided a dementia nursing educational programme alongside other local initiatives.  These activities supported the 4 key objectives in the DH implementation plan for Living Well with Dementia - A National Dementia Strategy and the NICE Quality Standards.  

2. What are the challenges to delivering these outcomes from the perspective of your organisation?

Since the updated NICE guidance (TA217) was published in April 2011, NHS Trusts have had a 3 month period to make arrangements for funding the new treatment recommendations.  Local feedback indicates many Trusts have successfully made these mandatory funding provisions through activities such as updating medicine formularies to reflect the NICE recommendations and supporting evidence base for clinical and cost effectiveness.

Member website

www.lundbeck.com

2. Actions

  • Partnership with local Trusts

    Continue to work in partnership with local Trusts to try to resolve mandatory funding issues for NICE guidance through our local Directors of Healthcare Development (DHD) and Mental Health Specialists (MHS).

    Status:

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA).

  • Providing tools as a service to medicine

    Providing tools as a service to medicine, that help enable NHS Organisations undertake reviews and carry out implementation in line with national guidance and objectives e.g. 

    • Reducing inappropriate prescribing of antipsychotics in dementia patients is a key national objective following the National Antipsychotic review, The National Dementia Strategy and more recently the NICE dementia care quality standards. Our Antipsychotic Review Programme supports PCOs in the identification of people with dementia who are prescribed antipsychotic medication.
    • Our Alzheimer’s NICE Implementation Review Programme (ANIR) contains a number of modules which can support NHS organisations in implementing NICE guidance TA217 both quickly and effectively. ANIR provides detailed intelligence about the prevalence of Alzheimer’s and other dementias, together with the provision of local services, and treatments provided. Using ANIR it will be possible for NHS organisations across primary and secondary care to collect data to answer specific questions, which they previously may have found time consuming and expensive, as well as to work together and use their data in an integrated way to facilitate implementation.
    Status:

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA).

  • Support education and training

    Continue to support education and training of healthcare professionals involved in the management of people with Alzheimer’s disease.

    Status:

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA) 

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA).

  • 2015/16: Progress research & development of pipeline medicines for Alzheimer's disease

    Lundbeck is currently researching medicines for Alzheimer's disease and has recently joined the the European Prevention of Alzheimer’s dementia (EPAD) Initiative. This is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The 5 year EPAD programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

    Status:
    Being implemented